Fearlessly Advancing


the first potential treatment
in geographic atrophy

Learn More


for people with PNH

Learn More
Leaders in Complement


at the forefront of targeted
C3 therapies

Learn More

With courageous science, creativity, and compassion,
we are committed to delivering therapies for people with
complement-driven diseases.

About Us
Folded page of a newspaper

Latest news

September 30, 2022

Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting

September 30, 2022

Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting

September 12, 2022

Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference

A man with a baby in a baby carrier

At the heart of our company is the belief that exceptional science and compassion are not mutually exclusive.

Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

Our groundbreaking science

targeting C3 offers the potential to provide comprehensive control of complement, a part of the immune system

Our Science
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

We aim to transform

treatment across a broad range of debilitating diseases driven by complement